Day One to Buy Mersana Therapeutics for Up to $285 Million

Dow Jones

Nov 13

By Colin Kellaher

Day One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash.

Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company.

Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share.

Shares of Mersana were recently up 215% at $27.95 in premarket trading.

Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options.

The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin.

Day One said it plans use cash on hand to finance the acquisition, which is slated to close by the end of January.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 13, 2025 06:23 ET (11:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583868561"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583868561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583868561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583868561","market":"sh","top_or_hot":-1,"title":"Day One to Buy Mersana Therapeutics for Up to $285 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> has struck a deal to buy fellow biopharmaceutical company Mersana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $285 million in cash. \n</p>\n<p>\n  Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company. \n</p>\n<p>\n  Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share. \n</p>\n<p>\n  Shares of Mersana were recently up 215% at $27.95 in premarket trading. \n</p>\n<p>\n  Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options. \n</p>\n<p>\n  The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin. \n</p>\n<p>\n  Day One said it plans use cash on hand to finance the acquisition, which is slated to close by the end of January. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 06:23 ET (11:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One to Buy Mersana Therapeutics for Up to $285 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One to Buy Mersana Therapeutics for Up to $285 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-13 19:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> has struck a deal to buy fellow biopharmaceutical company Mersana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $285 million in cash. \n</p>\n<p>\n  Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company. \n</p>\n<p>\n  Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share. \n</p>\n<p>\n  Shares of Mersana were recently up 215% at $27.95 in premarket trading. \n</p>\n<p>\n  Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options. \n</p>\n<p>\n  The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin. \n</p>\n<p>\n  Day One said it plans use cash on hand to finance the acquisition, which is slated to close by the end of January. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 06:23 ET (11:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2583868561","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583868561","pubTimestamp":1763032980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Day One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash.Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company.Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share.Shares of Mersana were recently up 215% at $27.95 in premarket trading.Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options.The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin.Day One said it plans us","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","MRSN":"Mersana Therapeutics Inc.","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics","DAWN":"Day One Biopharmaceuticals Inc.","BK4539":"次新股"},"translate_title":"第一天以高达2.85亿美元收购Mersana Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":0.9,"LENZ":1.5,"MRSN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\nDay One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash. \n\n\n  Day One on Thursday said it will pay an initial $25 a share, or $119 million, for Mersana, nearly triple Wednesday's closing price of $8.87 for the Cambridge, Mass., clinical-stage company. \n\n\n  Mersana shareholders will also receive contingent value rights worth up to an additional $30.25 a share, for a total potential deal consideration of $55.25 a share. \n\n\n  Shares of Mersana were recently up 215% at $27.95 in premarket trading. \n\n\n  Day One, based in Brisbane, Calif., said the acquisition of Mersana bolsters its portfolio with the antibody-drug conjugate emiltatug ledadotin, which has shown early anti-tumor activity in a Phase 1 study in adenoid cystic carcinoma type-1, a cancer with high unmet need and a lack of therapeutic options. \n\n\n  The contingent value rights in the deal are tied to development and sales milestones for emiltatug ledadotin. \n\n\n  Day One said it plans use cash on hand to finance the acquisition, which is slated to close by the end of January. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 06:23 ET (11:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}